Eli Lilly's Mounjaro and Zepbound drove Q2 2025 revenue up 38% and EPS up 92% YoY. Read why LLY stock's recent 20% pullback ...

Novo Nordisk said on Friday the US Food and Drug Administration has granted accelerated approval for its weight-loss drug Wegovy to treat a serious liver ...

There’s a new kind of nosy parker on the rise in the United States, a person who thinks it’s fine to blurt out “Are you on ...

Eli Lilly's obesity drugs delivered 38% revenue growth in the second quarter; but its oral GLP-1 candidate fell short, ...

It’s no secret that obesity is becoming an epidemic in the United  States. It’s estimated that by 2030, 50 percent of ...

The cost of Mounjaro, a popular weight-loss injection, is set to rise sharply in the UK – from £122 to £330 – a 170 per cent ...

"Forever" PFAS chemicals might hamper a teenager's ability to drop excess weight, even if they've undergone weight-loss surgery, researchers said in a study.

Trump’s push for price cuts and tariffs weighs on ‘obesity franchises’, which have missed out on equity market’s rise ...

The integration aims to simplify access to Zepbound for eligible members while providing comprehensive, whole-person care to ...

Doctors and many patients say GLP-1 drugs can help solve the growing problem of obesity. But some bristle at the thought that ...

Texas Attorney General Ken Paxton has filed a lawsuit against U.S. pharmaceutical giant Eli Lilly, alleging the company ...

Eli Lilly's experimental GLP-1 pill shows promise in a Phase Three trial, helping users lose an average of 12% of body weight, potentially transforming diabetes and obesity treatment.